Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. Donanemab was developed by Eli Lilly and Company. From Wikipedia
Without swift policy and service changes, access will remain uneven with widening inequities.
